Beam Therapeutics Inc 8-K, filed Jun 10, 2022
Beam Therapeutics Inc. (BEAM)
About this 8-K
Beam Therapeutics Inc filed this 8-K on June 10, 2022, reporting on events of June 8, 2022.
Items reported
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 8, 2022, Beam Therapeutics Inc. (the “Company”) held its 2022 annual meeting of stockholders (the “Annual Meeting”). The following are the voting results for the proposals considered and voted upon at the Annual Meeting, all of which were described in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 22, 2022 (the “Proxy Statement”).
Proposal 1 – Each of the following nominees were elected as Class II directors to serve on the Company’s board of directors until the Company’s 2025 annual meeting of stockholders, and until their respective successors have been duly elected and qualified, based on the following votes:
Nominee |
|
For |
|
|
Against |
|
|
Abstentions |
|
|
Broker Non-Votes |
|
||||
Mark Fishman, M.D. |
|
|
39,538,400 |
|
|
|
3,050,842 |
|
|
|
14,597 |
|
|
|
12,424,202 |
|
Carole Ho, M.D |
|
|
39,552,253 |
|
|
|
3,037,417 |
|
|
|
14,169 |
|
|
|
12,424,202 |
|
Kathleen Walsh |
|
|
40,267,444 |
|
|
|
2,322,120 |
|
|
|
14,275 |
|
|
|
12,424,202 |
|
Proposal 2 - The appointment of Deloitte &
Proposal 2 – The appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2022 was ratified, based on the following votes:
For |
|
|
Against |
|
|
Abstentions |
|
|
|
|
|||
|
51,756,591 |
|
|
|
3,094,353 |
|
|
|
177,097 |
|
|
|
|
Proposal 3 – The compensation of the Company’s named executive officers was approved, on an advisory basis, based on the following votes:
For |
|
|
Against |
|
|
Abstentions |
|
|
Broker Non-Votes |
|
||||
|
36,909,337 |
|
|
|
5,650,791 |
|
|
|
43,711 |
|
|
|
12,424,202 |
|
Proposal 4 – The stockholders voted to indicate, on an advisory basis, every year as the preferred frequency of stockholder advisory votes on the compensation of the Company’s named executive officers, based on the following votes:
Every Year |
|
|
2 Years |
|
3 Years |
|
|
Abstentions |
|
|
|||
|
39,292,270 |
|
|
3,164,472 |
|
|
107,936 |
|
|
|
39,161 |
|
|
Consistent with the stockholder voting results above and the recommendation of the board of directors of the Company as disclosed in the Proxy Statement, the board of directors of the Company has determined to solicit a non-binding advisory vote on the compensation of the Company’s named executive officers every year until the next required stockholder vote on the frequency of such non-binding advisory vote, or until the board of directors of the Company determines that a different frequency of such non-binding advisory vote is in the best interest of the Company’s stockholders.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
Beam Therapeutics Inc. |
|
|
|
|
Date: |
June 10, 2022 |
By: |
/s/ John Evans |
|
|
|
John Evans |